Related Experiment Video
Updated: Mar 1, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
A meta-analysis of montelukast for recurrent wheeze in preschool children
Hasan R Hussein1,2, Atul Gupta1,2, Simon Broughton1
1Faculty of Life Sciences & Medicine, Kings College London, London, UK.
Abstract:
There is conflicting evidence of the effectiveness of montelukast in preschool wheeze. A recent Cochrane review focused on its use in viral-induced wheeze; however, such subgroups are unlikely to exist in real life and change with time, recently highlighted in an international consensus report. We have therefore sought to investigate the effectiveness of montelukast in all children with preschool wheeze (viral-induced and multiple-trigger wheeze). The PubMed, Cochrane Library, Ovid Medline and Ovid EMBASE were screened for randomised controlled trials (RCTs), examining the efficacy of montelukast compared with placebo in children with the recurrent preschool wheeze. The primary endpoint examined was frequency of wheezing episodes. Five trials containing 3960 patients with a preschool wheezing disorder were analysed. Meta-analyses of studies of intermittent montelukast showed no benefit in preventing episodes of wheeze (mean difference (MD) 0.07, 95% confidence interval (CI) -0.14 to 0.29; mean for montelukast 2.68 vs placebo 2.54 (p = 0.5)), reducing unscheduled medical attendances (MD -0.13, 95% CI -0.33 to 0.07; mean for montelukast 1.62 vs placebo 1.78 (p = 0.21)) and reducing oral corticosteroids (MD -0.06, 95% CI -0.16 to 0.02; mean for montelukast 0.35 vs placebo 0.36 (p = 0.25)). The pooled results of the continuous regimen showed no significant difference in the number of wheezing episodes between the montelukast and placebo groups (MD -0.40, 95% CI -1.00 to 0.19; mean for montelukast 2.05 vs placebo 2.37 (p = 0.18)).
Conclusions:
This review highlights that the currently available evidence does not support the use of montelukast in preschool children with recurrent wheeze. We recommend further studies to investigate if a 'montelukast responder' phenotype exists, and how these can be easily identified in the clinical setting. What is Known: • Current guidelines recommend montelukast use in preschool children with recurrent wheeze. • A recent Cochrane review has found montelukast to be ineffective at reducing courses of oral corticosteroids for viral-induced wheeze. What is New: • This meta-analysis has examined all children with preschool wheeze and found that montelukast was not effective at preventing wheezing episodes or reducing unscheduled medical attendances. • A specific montelukast responder phenotype may exist, but such patients should be sought in larger multicentre RCTs.
Insights
Montelukast is not effective for treating preschool wheeze, failing to prevent episodes or reduce medical visits. Further research is needed to identify potential
Area of Science:
- Pediatric Pulmonology
- Pharmacology
- Clinical Trials
Background:
- Conflicting evidence exists regarding montelukast's effectiveness in preschool wheeze.
- Previous reviews focused on viral-induced wheeze, a subgroup with limited real-world applicability.
- International consensus highlights the evolving nature of wheeze phenotypes in young children.
Purpose of the Study:
- To investigate the efficacy of montelukast in all children diagnosed with preschool wheeze.
- To evaluate montelukast's impact on wheezing episodes, unscheduled medical attendances, and oral corticosteroid use.
- To synthesize evidence from randomized controlled trials comparing montelukast with placebo.
Main Methods:
- Systematic screening of PubMed, Cochrane Library, Ovid Medline, and Ovid EMBASE for relevant randomized controlled trials (RCTs).
- Inclusion criteria focused on children with recurrent preschool wheeze treated with montelukast versus placebo.
- Primary endpoint was the frequency of wheezing episodes; secondary endpoints included unscheduled medical attendances and oral corticosteroid use.
Main Results:
- Meta-analysis of intermittent montelukast showed no significant benefit in preventing wheeze episodes (MD 0.07, p=0.5).
- Montelukast did not significantly reduce unscheduled medical attendances (MD -0.13, p=0.21) or oral corticosteroid use (MD -0.06, p=0.25).
- Continuous montelukast regimens also showed no significant difference in wheezing episodes compared to placebo (MD -0.40, p=0.18).
Conclusions:
- Current evidence does not support the use of montelukast for preschool children experiencing recurrent wheeze.
- The study suggests that a specific 'montelukast responder' phenotype may exist but requires further investigation.
- Larger multicenter RCTs are recommended to identify and characterize potential montelukast responders in clinical practice.
More Related Videos
Related Concept Videos
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-III: Symptoms and Complications
Classification of Asthma

